Navigation Links
Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
Date:11/13/2007

ects with ALT elevations on-treatment or during 90 days

following the last study dose

Max ALT** Placebo 30/50 100 200 >=300

mg/week mg/week mg/week mg/week

(N=40) (N=35) (N=35) (N=87) (N=106)

150-250 5% 9% 0% 7% 14%

IU/L

(3xULN-

5xULN***)

>250 IU/L 0% 0% 0% 1% 4%

(>5xULN***)

** Each subject is counted only once at maximum ALT reading

*** ULN is defined to be 50 IU/L

About Mipomersen and Cholesterol

Mipomersen, formerly ISIS 301012, is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, being the good form, and low-density lipoproteins, or LDL-C, and very low-density lipoproteins, or VLDL-C, being bad forms directly involved in heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a key component in the prevention and management of cardiovascular disease. Isis plans to develop mipomersen as the drug of choice for patients who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins. Isis is developing mipomersen at a dose of 200 mg/week in its ongoing and future studies.

Analyst & Investor Day Information

At 9:00 a.m. Eastern Standard Time Tuesday, November 13, Isis will conduct a live webcast presentation of its Analyst & Investor Day. Interested parties may access the webcast at http://www.isispharm.com. A replay
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Cymetrix, a leader in providing healthcare organizations ... an alliance with Siemens Healthcare for financial system ... Cymetrix will assist in the transition of select ... to Siemens Soarian®. Cymetrix,s system conversion solution preserves ...
... HORSHAM, Pa., Dec. 7, 2010 Topaz Pharmaceuticals Inc., ... completion of two Phase 3 clinical trials that studied ... treatment for head lice. These trials were conducted according ... Food and Drug Administration (FDA). "Parents and ...
Cached Medicine Technology:Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support 2Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream 2Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable ... from 3 p.m. to 4 p.m. on Feb. 13. , The ... serves adults with physical disabilities between the ages of 22 and ... games and sweetheart-themed karaoke. , For more information about the event ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... CAMBRIDGE, Mass., Oct. 28 Biopure Corporation,(Nasdaq: ... a notice from the,Medicines Control Council (MCC) of ... of Hemopure [hemoglobin glutamer-250,(bovine)], Biopure,s oxygen therapeutic for ... intends to appeal the decision promptly and,expects to ...
... Periodontal disease rises as the joint ailment worsens, research ... arthritis (RA) may increase the risk of gum disease, ... a link between RA and periodontal disease, a condition ... teeth from the gums, loss of bony support, and ...
... NEWPORT BEACH, Calif., Oct. 28 Nationwide,Health Properties, Inc. ... of,Directors declared a $0.44 per share dividend on our ... to shareholders of record on November 14, 2008., ... per share,dividend on our Series B cumulative convertible preferred ...
... Oct. 28 IRIDEX,Corporation (Nasdaq: IRIX ) today ... results after the market closes on Tuesday, November,4, 2008. ... a,conference call with the investment community at 5:00 p.m. ... results of the quarter and other,business developments., Interested ...
... (TSX: RBM, OTCBB: RPBIF) (the "Company") today announced ... financing announced on October,14, 2008 and amended on ... The closing involved a brokered and non-brokered private ... for each unit. Each unit consisted,of one common ...
... 26, 2008) A single administration of a novel, nasally ... were more than 20 times higher than those generated ... to a study by NanoBio Corporation. The new vaccine ... this effect. , Results of the study are being ...
Cached Medicine News:Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 2Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 3Health News:Rheumatoid Arthritis May Harm Gums 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:New intranasal influenza vaccine triggers robust immunity with significantly less antigen 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: